Thermo Fisher acquires IntegenX for enhancing HID portfolio

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

IntegenX products significantly enhance Thermo Fisher’s existing HID portfolio and complement its leading human identification chemistries.

Thermo Fisher Scientific Inc., the world leader in serving science, recently announced that it has acquired IntegenX Inc., which provides a rapid DNA platform for use in forensics and law enforcement applications.

IntegenX products significantly enhance Thermo Fisher’s existing HID portfolio and complement its leading human identification chemistries, as well as its qPCR and capillary electrophoresis systems.

IntegenX solutions include the RapidHIT platforms, software analysis tools and related consumables that are highly compatible with Thermo Fisher’s short tandem repeat (STR) chemistries for human identification.

IntegenX currently provides support to prosecutors and law enforcement in 17 countries where its technology is used in government laboratories to generate forensic DNA profiles from samples in 90 minutes as opposed to the standard processing time of three weeks.